ARCHIVES

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Schmidt Asks NCI Grantees, Contractors To tell Him How They Waste Cancer Money

December 13, 1974

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

December 26, 2014

Progress Requires More Etiologists, D’Angio Says

September 15, 1978

FCRF Recompetition Intriguing, Involved Various Possibility

May 9, 1986

Senate Approves Supplemental Funds For NIH and FDA.

May 23, 2008

House subcommittee proposes 2.8 percent increase for NIH, NCI.

July 16, 2004